Lilly reports detailed Phase III data for Cyramza in first-line gastric cancer

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III RAINFALL trial in 645 patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma showing that IV Cyramza ramucirumab (IMC-1121B, LY3009806) plus cisplatin and capecitabine or 5-fluorouracil as first-line treatment led to a median progression-free survival (PFS), the primary endpoint, of 5.7 months vs 5.4 months for chemotherapy alone (HR=0.75, 95% CI: 0.61, 0.94, p=0.011). The data were released in an abstract presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

On a secondary endpoint, Cyramza plus chemotherapy led to a median overall survival (OS) of 11.2 months vs. 10.7 months for chemotherapy alone (HR=0.96, 95% CI: 0.8, 1.16, p=0.68). Cyramza plus chemotherapy led to an objective response rate (ORR) of 41.1% vs. 36.4% for chemotherapy alone...